Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2021

19.06.2020 | Original Article

The Association of Pre-diagnostic Inflammatory Markers and Adipokines and the Risk of Non-Hodgkin Lymphoma Development in Egypt

verfasst von: Doaa Mohamed El Demerdash, Nehad Mohamed Tawfik, Raghda Elazab, Maha Hamdi El Sissy

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Non-Hodgkin lymphoma (NHL) is an etiologically, clinically, and histologically heterogeneous group of lymphoproliferative disorders. Immune dysfunction is a well-known risk factor and dysregulation of cytokines may mediate disease progression. Obesity is one of the important relations connecting immune system abnormalities and lymphomagenesis. We conducted a study to find out the association between obesity as measured by body mass index (BMI), and risk of non-Hodgkin lymphoma (NHL) development by assessment the of inflammatory cytokines levels, (IL-6, IL-10, IFN-gamma and CRP) and adipokines levels (leptin and adiponectin). Also, to predict the effect of higher BMI on the incidence of NHL. The study included 180 NHL patients and 172 healthy controls. The inflammatory markers (IL-6, IL-10, IFN-γ & CRP) together with adiponectin were assessed by ELISA technique. IL-6, IL-10, CRP, IFN-γ and Adiponectin were statistically higher in cases than control. A positive significant difference of Leptin (p-value 0.001) was found with higher levels in patients with BMI (≥ 25 kg/m2) than in patients with < 25 kg/m2. IL-6, IL-10, CRP, IFN-γ and Adiponectin could be implicated in lymphomagenesis in Egyptian NHL. The study results support the hypothesis that obesity has a major role in the development of NHL. An association between Leptin and NHL risk with higher levels in patients with BMI (≥ 25 kg/m2) was proved.
Literatur
1.
Zurück zum Zitat Ekstrom SK, Vajdic CM, Falster M et al (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the inter lymph consortium. Blood 111:4029–4038CrossRef Ekstrom SK, Vajdic CM, Falster M et al (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the inter lymph consortium. Blood 111:4029–4038CrossRef
2.
Zurück zum Zitat Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556CrossRef Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556CrossRef
3.
Zurück zum Zitat Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–767CrossRef Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–767CrossRef
4.
Zurück zum Zitat Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355CrossRef Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355CrossRef
5.
Zurück zum Zitat De Pergola G, Silvestris F (2013) Obesity as a major risk factor for cancer. J Obes 2013:291546CrossRef De Pergola G, Silvestris F (2013) Obesity as a major risk factor for cancer. J Obes 2013:291546CrossRef
6.
Zurück zum Zitat Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32:2601–2613CrossRef Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32:2601–2613CrossRef
7.
Zurück zum Zitat Gopal A, Kahl B, de Vos S, Wagner-Johnston ND, Schuster SJ, Blum KA et al (2014) Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Clin Adv Hematol Oncol 12:8–9 Gopal A, Kahl B, de Vos S, Wagner-Johnston ND, Schuster SJ, Blum KA et al (2014) Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Clin Adv Hematol Oncol 12:8–9
8.
Zurück zum Zitat Beltowski J, Jamroz-Wisniewska A, Widomska S (2008) Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 8:7–46CrossRef Beltowski J, Jamroz-Wisniewska A, Widomska S (2008) Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 8:7–46CrossRef
9.
Zurück zum Zitat Saxena NK, Sharma D (2010) Metastasis suppression by adiponectin: LKB1 rises up to the challenge. Cell Adh Migr 4:358–362CrossRef Saxena NK, Sharma D (2010) Metastasis suppression by adiponectin: LKB1 rises up to the challenge. Cell Adh Migr 4:358–362CrossRef
10.
Zurück zum Zitat Cerhan JR, Slager SL (2015) Familial predisposition and genetic risk factors for lymphoma. Blood 126:2265–2273CrossRef Cerhan JR, Slager SL (2015) Familial predisposition and genetic risk factors for lymphoma. Blood 126:2265–2273CrossRef
11.
Zurück zum Zitat Roberts D, Dive C, Renehan A (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Ann Rev Med 61:301–316CrossRef Roberts D, Dive C, Renehan A (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Ann Rev Med 61:301–316CrossRef
12.
Zurück zum Zitat Renehan AG (2011) Epidemiology of overweight/obesity and cancer risk. In: McTiernan A (ed) Physical activity, dietary calorie restriction, and cancer, vol 3. Springer, New York, pp 5–23CrossRef Renehan AG (2011) Epidemiology of overweight/obesity and cancer risk. In: McTiernan A (ed) Physical activity, dietary calorie restriction, and cancer, vol 3. Springer, New York, pp 5–23CrossRef
13.
Zurück zum Zitat Conroy SM, Maskarinec G, Morimoto Y et al (2013) Non-Hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 22(3):337–347CrossRef Conroy SM, Maskarinec G, Morimoto Y et al (2013) Non-Hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 22(3):337–347CrossRef
14.
Zurück zum Zitat Hadi DA, Shani WS, Khalaf AA et al (2013) Serum levels of interleukin-6 and interleukin-10 in adult newly diagnosed Iraqi non-Hodgkin’s lymphoma patients. Euro J Exp Bio 3(5):441–446 Hadi DA, Shani WS, Khalaf AA et al (2013) Serum levels of interleukin-6 and interleukin-10 in adult newly diagnosed Iraqi non-Hodgkin’s lymphoma patients. Euro J Exp Bio 3(5):441–446
15.
Zurück zum Zitat Hsu SM, Xie SS, Waldron JA (1992) Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas. Am J Pathol 141(4):915–923PubMedPubMedCentral Hsu SM, Xie SS, Waldron JA (1992) Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas. Am J Pathol 141(4):915–923PubMedPubMedCentral
16.
Zurück zum Zitat Purdue MP, Lan Q, Bagni R et al (2011) Prediagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin Lymphoma. Cancer Res 71(14):4898–4907CrossRef Purdue MP, Lan Q, Bagni R et al (2011) Prediagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin Lymphoma. Cancer Res 71(14):4898–4907CrossRef
17.
Zurück zum Zitat Guney N, Soydinc HO, Basaran M et al (2009) Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma. Asian Pac J Cancer Prev 10(4):669–674PubMed Guney N, Soydinc HO, Basaran M et al (2009) Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma. Asian Pac J Cancer Prev 10(4):669–674PubMed
18.
Zurück zum Zitat Epeldegui M, Widney DP, Martinez-Maza O (2006) Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 18:444–448CrossRef Epeldegui M, Widney DP, Martinez-Maza O (2006) Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 18:444–448CrossRef
19.
Zurück zum Zitat Voorzanger N, Touitou R, Garcia E et al (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res 56:5499–5505PubMed Voorzanger N, Touitou R, Garcia E et al (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res 56:5499–5505PubMed
20.
Zurück zum Zitat Chen Y, Zheng T, Lan Q et al (2011) Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 117:585–590CrossRef Chen Y, Zheng T, Lan Q et al (2011) Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 117:585–590CrossRef
21.
Zurück zum Zitat Saberi HF, Krop EJ, Scoccianti C et al (2010) Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 19:1577–1584CrossRef Saberi HF, Krop EJ, Scoccianti C et al (2010) Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 19:1577–1584CrossRef
22.
Zurück zum Zitat Shivappa N, He’bert JR, Taborelli M et al (2017) Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case–control study. Cancer Causes Control 28:791–799CrossRef Shivappa N, He’bert JR, Taborelli M et al (2017) Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case–control study. Cancer Causes Control 28:791–799CrossRef
23.
Zurück zum Zitat Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the inter lymph consortium. Lancet Oncol 7(1):27–38CrossRef Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the inter lymph consortium. Lancet Oncol 7(1):27–38CrossRef
24.
Zurück zum Zitat La CA, Matarese G (2004) The weight of leptin in immunity. Nat Rev Immunol 4:371–379CrossRef La CA, Matarese G (2004) The weight of leptin in immunity. Nat Rev Immunol 4:371–379CrossRef
25.
Zurück zum Zitat Skibola CF, Holly EA, Forrest MS et al (2004) Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 13(5):779–786PubMed Skibola CF, Holly EA, Forrest MS et al (2004) Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 13(5):779–786PubMed
26.
Zurück zum Zitat Willett EV, Skibola CF, Adamson P et al (2005) Non-Hodgkin’s lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer 93:811–816CrossRef Willett EV, Skibola CF, Adamson P et al (2005) Non-Hodgkin’s lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer 93:811–816CrossRef
27.
Zurück zum Zitat Dalamaga M, Diakopoulos KN, Mantzoros CS (2012) The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33(4):547–594CrossRef Dalamaga M, Diakopoulos KN, Mantzoros CS (2012) The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33(4):547–594CrossRef
28.
Zurück zum Zitat Petridou ET, Sergentanis TN, Dessypris N et al (2009) Serum adiponectin as a predictor of childhood non-Hodgkin’s lymphoma: a nationwide case-control study. J Clin Oncol 27:5049–5055CrossRef Petridou ET, Sergentanis TN, Dessypris N et al (2009) Serum adiponectin as a predictor of childhood non-Hodgkin’s lymphoma: a nationwide case-control study. J Clin Oncol 27:5049–5055CrossRef
29.
Zurück zum Zitat Pamuk GE, Turgut B, Demir M et al (2006) Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome. J Exp Clin Cancer Res 25:537–541PubMed Pamuk GE, Turgut B, Demir M et al (2006) Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome. J Exp Clin Cancer Res 25:537–541PubMed
30.
Zurück zum Zitat Wei T, Ye P, Xin PX et al (2016) circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies. Oncotarget 7(30):48671–48691CrossRef Wei T, Ye P, Xin PX et al (2016) circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies. Oncotarget 7(30):48671–48691CrossRef
31.
Zurück zum Zitat Hellström L, Wahrenberg H, Hruska K et al (2000) Mechanisms behind gender difference in circulating leptin levels. J Intern Med 247:457–462CrossRef Hellström L, Wahrenberg H, Hruska K et al (2000) Mechanisms behind gender difference in circulating leptin levels. J Intern Med 247:457–462CrossRef
32.
Zurück zum Zitat Kelly JL, Fredericksen ZS, Liebow M et al (2012) The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. Ann Epidemiol 22:855–862CrossRef Kelly JL, Fredericksen ZS, Liebow M et al (2012) The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. Ann Epidemiol 22:855–862CrossRef
33.
Zurück zum Zitat Patel AV, Diver WR, Teras LR et al (2013) Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma 54(6):1221–1227CrossRef Patel AV, Diver WR, Teras LR et al (2013) Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma 54(6):1221–1227CrossRef
34.
Zurück zum Zitat Bertrand KA, Giovannucci E, Zhang SM et al (2013) A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. Cancer Prev Res 6(8):864–873CrossRef Bertrand KA, Giovannucci E, Zhang SM et al (2013) A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. Cancer Prev Res 6(8):864–873CrossRef
35.
Zurück zum Zitat Golubovic I, Marjanovic G, RadojKovic D et al (2017) Overweight, obesity and physical activity in relation to follicular lymphoma incidence and mortality: a meta-analysis. Arch Pathol Clin Res 1:024–034 Golubovic I, Marjanovic G, RadojKovic D et al (2017) Overweight, obesity and physical activity in relation to follicular lymphoma incidence and mortality: a meta-analysis. Arch Pathol Clin Res 1:024–034
36.
Zurück zum Zitat Winer DA, Winer S, Chng MH et al (2014) B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. Cell Mol Life Sci 71:1033–1043CrossRef Winer DA, Winer S, Chng MH et al (2014) B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. Cell Mol Life Sci 71:1033–1043CrossRef
Metadaten
Titel
The Association of Pre-diagnostic Inflammatory Markers and Adipokines and the Risk of Non-Hodgkin Lymphoma Development in Egypt
verfasst von
Doaa Mohamed El Demerdash
Nehad Mohamed Tawfik
Raghda Elazab
Maha Hamdi El Sissy
Publikationsdatum
19.06.2020
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2021
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01305-9

Weitere Artikel der Ausgabe 1/2021

Indian Journal of Hematology and Blood Transfusion 1/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.